Cytek Biosciences, Inc. (CTKB) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CTKB currently has 129M outstanding shares. with limited dilution risk as only 13.9M additional shares (10.8%) are authorized for issuance. The company has minimally diluted shareholders by 0.28% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 128.7M shares outstanding |
130M | 14M |
| May 08, 2025 |
10-Q filing | 128.3M shares outstanding |
130M | 14M |
| Feb 28, 2025 |
10-K filing | 130.6M shares outstanding |
130M | 14M |
| Nov 07, 2024 |
10-Q filing | 131.0M shares outstanding |
130M | 14M |
| Aug 06, 2024 |
10-Q filing | 131.4M shares outstanding |
130M | 14M |
| May 08, 2024 |
10-Q filing | 130.9M shares outstanding |
130M | 14M |
| Mar 13, 2024 |
10-K filing | 135.3M shares outstanding |
140M | 14M |
| Nov 14, 2023 |
10-Q filing | 136.2M shares outstanding |
140M | 14M |
| Aug 08, 2023 |
10-Q filing | 135.9M shares outstanding |
140M | 14M |
| May 09, 2023 |
10-Q filing | 135.5M shares outstanding |
140M | 14M |
| Mar 01, 2023 |
10-K filing | 134.5M shares outstanding |
130M | 14M |
| Nov 09, 2022 |
10-Q filing | 134.7M shares outstanding |
130M | 14M |
| Aug 10, 2022 |
10-Q filing | 134.4M shares outstanding |
130M | 14M |
| May 12, 2022 |
10-Q filing | 133.9M shares outstanding |
130M | 14M |
| Mar 17, 2022 |
10-K filing | 134.1M shares outstanding |
130M | 14M |
| Nov 12, 2021 |
10-Q filing | 133.7M shares outstanding |
130M | 14M |
| Sep 03, 2021 |
10-Q filing | 46.4M shares outstanding |
46M | 14M |
| Jul 19, 2021 |
S-1/A filing: This is an S-1/A filing including information on recent sales of unregistered securities, including Series B, C and D redeemable convertible preferred stock, options to purchase common stock, and common stock issued upon exercise of options. |
N/A | 14M |
| Jul 14, 2021 |
S-1/A filing: This is an S-1/A filing including information on recent sales of unregistered securities, including Series B, C, and D redeemable convertible preferred stock, and common stock issued upon the exercise of options and to Becton, Dickinson and Company. |
N/A | 3.6M |
| Jul 02, 2021 |
S-1 filing: This is an S-1 filing for Cytek Biosciences, Inc. The document details recent sales of unregistered securities, including preferred stock, common stock options, and common stock issuances. |
N/A | 8.3M |